Share on StockTwits

BTG plc (LON:BTG)‘s stock had its “sell” rating reaffirmed by equities research analysts at FinnCap in a research note issued to investors on Wednesday. They currently have a GBX 345 ($5.91) price objective on the stock. FinnCap’s price target suggests a potential downside of 44.89% from the stock’s previous close.

BTG plc (LON:BTG) traded up 0.08% on Wednesday, hitting GBX 626.00. 444,528 shares of the company’s stock traded hands. BTG plc has a 52-week low of GBX 363.00 and a 52-week high of GBX 665.00. The stock’s 50-day moving average is GBX 618.5 and its 200-day moving average is GBX 581.8. The company’s market cap is £2.259 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at Investec raised their price target on shares of BTG plc from GBX 723 ($12.38) to GBX 728 ($12.46) in a research note on Wednesday, July 2nd. They now have a “buy” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of BTG plc in a research note on Wednesday, July 2nd. They now have a GBX 655 ($11.21) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of BTG plc in a research note on Tuesday, July 1st. Three analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. BTG plc has an average rating of “Hold” and a consensus target price of GBX 536.88 ($9.19).

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.